Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1-Reference-Cited by-同舟云学术

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1

Published:2022-09-23 Issue:11 Volume:36 Page:2729-2733
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Fiskus Warren^ORCID,Daver Naval^ORCID,Boettcher Steffen^ORCID,Mill Christopher P.,Sasaki Koji^ORCID,Birdwell Christine E.,Davis John A.,Das Kaberi^ORCID,Takahashi Koichi^ORCID,Kadia Tapan M.^ORCID,DiNardo Courtney D.^ORCID,Burrows Francis,Loghavi Sanam^ORCID,Khoury Joseph D.^ORCID,Ebert Benjamin L.^ORCID,Bhalla Kapil N.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-022-01707-w.pdf

Reference15 articles.

1. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7:823–33.

2. Li X, Song Y. Structure, function and inhibition of critical protein-protein interactions involving mixed lineage leukemia 1 and its fusion oncoproteins. J Hematol Oncol. 2021;14:56.

3. Milne TA, Kim J, Wang GG, Stadler SC, Basrur V, Whitcomb SJ, et al. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol Cell. 2010;38:853–63.

4. Argiropoulos B, Yung E, Humphries RK. Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis. Genes Dev. 2007;21:2845–9.

5. Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, et al. HOXA9 reprograms the enhancer landscape to promote leukemogenesis. Cancer Cell. 2018;34:643–58e5.

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Prediction and Streamline of Nucleophosmin Mutation Status in Acute Myeloid Leukemia Using Cup-Like Nuclear Morphology;Medicina;2024-09-04

2. Menin signaling and therapeutic targeting in breast cancer;Current Problems in Cancer;2024-08

3. Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?;American Journal of Hematology;2024-07-17

4. Therapeutic Targeting of the Menin–KMT2A Interaction;Annual Review of Cancer Biology;2024-06-12

5. Distinct Responses to Menin Inhibition and Synergy with DOT1L Inhibition in KMT2A-Rearranged Acute Lymphoblastic and Myeloid Leukemia;International Journal of Molecular Sciences;2024-05-30